Bottneuro | Precision Medicine for Brain Health
Bottneuro strives to set new standards in personalized neuromodulation - achieving better results and improving quality of life. Find out more!
Overview
Bottneuro AG is a clinical-stage neurotechnology company headquartered at Lichtstrasse 35. The company develops disease-modifying neuromodulation therapies targeting conditions such as Alzheimer’s, depression, stroke, and epilepsy. Bottneuro utilizes its personalized Miamind® technology to enhance treatment outcomes and improve the quality of life for patients.
Details
- Category
- Medical Equipment Manufacturing
- Headquarters
- Lichtstrasse 35
- Type
- Privately Held
- Founded
- 2021
- Specialties
- Precision medicine, personalized medicine, Non-invasive stimulation, 3D printing, Alzheimer, electrical stimulation, MRI, and neurotechnology
- Locations
- Novartis Campus Lichtstrasse 35 Lichtstrasse 35, 4056, CH
Marie-Curie Straße 8 Lörrach, Baden-Württemberg 79539, DE
2261 Market St San Francisco, California 94114, US
Funding
Total rounds: 3
Last round: Convertible note, Jan 15, 2023
Last round amount: US$ 4.3M